CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: Consequently, dasatinib could be useful, especially in the patients that do not have these protective features, to enhance cytotoxic activity of NK cells against CML cells by increasing memory-like NKG2C+CD57+ NK cells [70], γδ T cells and other innate CD8+ T cells [7,30,37,44].